PMCB Valuation

PharmaCyte Biotech Inc

Add to Watchlist

Advanced Chart

0.842

-0.043(-4.857%)1D

PMCB Relative Valuation

PMCB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PMCB is overvalued; if below, it's undervalued.

Historical Valuation

PharmaCyte Biotech Inc (PMCB) is now in the Fair zone, suggesting that its current forward PS ratio of 0.89 is considered Fairly compared with the five-year average of -9.62. The fair price of PharmaCyte Biotech Inc (PMCB) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：0.89

Fair

-2.33

Trailing

Forward

0.00

EV/EBITDA

PharmaCyte Biotech Inc. (PMCB) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.

0.85

EV/EBIT

PharmaCyte Biotech Inc. (PMCB) has a current EV/EBIT of 0.85. The 5-year average EV/EBIT is 1.56. The thresholds are as follows: Strongly Undervalued below -7.83, Undervalued between -7.83 and -3.13, Fairly Valued between 6.26 and -3.13, Overvalued between 6.26 and 10.96, and Strongly Overvalued above 10.96. The current Forward EV/EBIT of 0.85 falls within the Historic Trend Line -Fairly Valued range.

0.89

PharmaCyte Biotech Inc. (PMCB) has a current PS of 0.89. The 5-year average PS is 0.01. The thresholds are as follows: Strongly Undervalued below -0.14, Undervalued between -0.14 and -0.07, Fairly Valued between 0.08 and -0.07, Overvalued between 0.08 and 0.16, and Strongly Overvalued above 0.16. The current Forward PS of 0.89 falls within the Strongly Overvalued range.

-0.79

P/OCF

PharmaCyte Biotech Inc. (PMCB) has a current P/OCF of -0.79. The 5-year average P/OCF is -4.57. The thresholds are as follows: Strongly Undervalued below -12.00, Undervalued between -12.00 and -8.29, Fairly Valued between -0.86 and -8.29, Overvalued between -0.86 and 2.85, and Strongly Overvalued above 2.85. The current Forward P/OCF of -0.79 falls within the Overvalued range.

0.00

P/FCF

PharmaCyte Biotech Inc. (PMCB) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/FCF of 0.00 falls within the Strongly Undervalued range.

PharmaCyte Biotech Inc (PMCB) has a current Price-to-Book (P/B) ratio of 0.14. Compared to its 3-year average P/B ratio of 0.45 , the current P/B ratio is approximately -69.05% higher. Relative to its 5-year average P/B ratio of 1.06, the current P/B ratio is about -87.03% higher. PharmaCyte Biotech Inc (PMCB) has a Forward Free Cash Flow (FCF) yield of approximately -0.76%. Compared to its 3-year average FCF yield of -20.02%, the current FCF yield is approximately -96.18% lower. Relative to its 5-year average FCF yield of -16.07% , the current FCF yield is about -95.24% lower.

0.14

P/B

Median3y

0.45

Median5y

1.06

-0.76

FCF Yield

Median3y

-20.02

Median5y

-16.07

Competitors Valuation Multiple

The average P/S ratio for PMCB's competitors is 3.71, providing a benchmark for relative valuation. PharmaCyte Biotech Inc Corp (PMCB) exhibits a P/S ratio of 0.89, which is -76.11% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

PMCB.O

PharmaCyte Biotech Inc

Qualigen Therapeutics Inc

Enveric Biosciences Inc

7.24

3.75M

SCNI.O

Scinai Immunotherapeutics Ltd

1.16

3.70M

Performance Decomposition

Market capitalization of PMCB increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of PMCB in the past 1 year is driven by Unknown.